Clinical trials of Covid-19 intravenous immunoglobulin (C-IVIG), a therapy developed by Dow University of Health Sciences (DUHS) against coronavirus, showed promising results, the medical institute revealed in a statement on Saturday.

C-IVIG has shown 100 per cent recovery rate in severe patients, and more than 60% recovery rate in critical patients admitted in ICU [intensive care unit] or are on ventilators, with more than 50% of the recovered patients being discharged from hospital within five days, it said.

The DUHS scientists conducted pre-clinical trials of C-IVIG in early April, after which the Drug Regulatory Authority Pakistan (DRAP) approved the clinical trial of the treatment on a fast-track.

https://tribune.com.pk/story/2273045/clinical-trials-of-pakistani-covid-19-treatment-show-promising-results